Santos Miguel Oliveira, Gromicho Marta, Pinto Susana, de Carvalho Mamede
a Institute of Physiology Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa , Lisboa , Portugal.
b Department of Neurosciences and Mental Health , Hospital de Santa Maria, Centro Hospitalar Lisboa Norte , Lisbon , Portugal.
Amyotroph Lateral Scler Frontotemporal Degener. 2018 Nov;19(7-8):619-622. doi: 10.1080/21678421.2018.1510010. Epub 2018 Sep 28.
Although amyotrophic lateral sclerosis (ALS) incidence has been stable among Western countries, population-ageing effect will probably increase the proportion of very-old ALS patients. We aim to study this population.
A retrospective study was performed, including 1083 ALS patients followed longitudinally in our ALS unit from January 1995 to December 2017. The patients were divided in two groups, according to age at disease onset (</≥80 years). Demographic, clinical, and survival data were compared between groups.
Fifty out of 1083 (4.62%) patients were aged 80 or over. Mean onset age in this group was 82.9 ± 2.59 years and 28 (56%) were men. Contrasting with the younger group, bulbar-onset was remarkably the most common presentation form (54%, p < 0.001), but with no gender preference (p = 0.52) and so was significantly shorter disease duration before first visit (13.41 ± 9.42 versus 18.84 ± 21.66 months, p = 0.001). Survival after disease onset (31.87 ± 25.45 versus 45.61 ± 39.93 months, respectively for older and younger groups, p = 0.001) was significantly dependent on age of onset, disease duration and onset form in the younger group while it was only dependent on onset form in the older group. No significant differences were observed regarding cognitive dysfunction, ALS/FTD familial history, non-invasive ventilation (NIV) or riluzole prescription.
Very-old patients represent a minor but distinctive ALS group. A predominant bulbar presentation was disclosed and it could probably explain the shorter disease duration before first visit as well as survival. Older age was not an exclusion factor for good health care practices, in particular NIV and riluzole prescription.
尽管西方国家肌萎缩侧索硬化症(ALS)的发病率一直保持稳定,但人口老龄化效应可能会增加高龄ALS患者的比例。我们旨在研究这一人群。
进行了一项回顾性研究,纳入了1995年1月至2017年12月在我们的ALS科室接受纵向随访的1083例ALS患者。根据疾病发病年龄(<80岁/≥80岁)将患者分为两组。比较两组之间的人口统计学、临床和生存数据。
1083例患者中有50例(4.62%)年龄在80岁及以上。该组的平均发病年龄为82.9±2.59岁,28例(56%)为男性。与较年轻组相比,延髓起病是最常见的表现形式(54%,p<0.001),但无性别差异(p=0.52),首次就诊前的病程也明显较短(13.41±9.42个月对18.84±21.66个月,p=0.001)。发病后的生存期(老年组和年轻组分别为31.87±25.45个月和45.61±39.93个月,p=0.001)在年轻组中显著取决于发病年龄、病程和起病形式,而在老年组中仅取决于起病形式。在认知功能障碍、ALS/FTD家族史、无创通气(NIV)或利鲁唑处方方面未观察到显著差异。
高龄患者是一个较小但独特的ALS群体。发现延髓起病占主导,这可能解释了首次就诊前较短的病程以及生存期。高龄并非良好医疗实践的排除因素,特别是NIV和利鲁唑处方。